Neurological Diseases & Injuries
Alzheimer’s disease is a progressive brain disorder that gradually destroys memory and other important mental functions. More than 90% of AD cases are the late-onset form, with symptoms not appearing until after 65 years of age. Two abnormal structures, plaques and tangles, are detected in affected brains. These are the prime suspects for increasing cell death and tissue loss.
Mesenchymal stem cells are actively being explored as a potential therapeutic option for immune-mediated diseases like Alzheimer’s.
|TRIAL HYPOTHESIS||CLINICAL TRIAL ID|
|Looking at the tolerability and safety of umbilical cord mesenchymal stem cells and the efficacy of using them to treat patients with alzheimer’s disease.||NCT01547689 Affiliated Hospital to Academy of Military Medical Sciences, China|
|Evaluating the safety and efficacy in using umbilical cord mesenchymal stem cells to treat Alzheimer’s.||NCT02672306 South China Research Center for Stem Cell and Regenerative Medicine|
|What is the maximum tolerated dose for NEUROSTEM®-AD (umbilical cord derived mesenchymal stem cells) for treating patients with dementia of Alzheimer’s type?||NCT01297218 Medipost Co Ltd, South Korea|
|Phase 1/2 a clinical trial looking at the effectiveness of treating alzheimer’s disease with intraventricular administration of NEUROSTEM®.||NCT02054208 Medipost Co Ltd, South Korea|